Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Second interim analysis of the EMN02 trial

Michele Cavo • 17 May 2019
COMy 2019
Multiple Myeloma
EMN02

Michele Cavo, MD, of Bologna University School of Medicine, Bologna, Italy, discusses the second interim analysis of the EMN02 trial (NCT01208766), which is the largest academic trial so far that aims to compare upfront transplant vs. standard dosing and consolidation vs. no consolidation for multiple myeloma. This interview was recorded at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France.

More from Michele Cavo

Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy 1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
The importance of MRD as a prognostic tool in multiple myeloma 1:36
The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo • 28 Sep 2023
CD38-targeting triplets for myeloma 1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
How has the role of transplant changed with the introduction of CAR-T therapy? 1:43
How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo • 17 May 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals